I Huntington. Huntington Huntington s disease HD HD HD. Huntington 1. HD polyq disease Qn. homozygotes heterozygotes. HD Huntington.
|
|
- Megan Payne
- 5 years ago
- Views:
Transcription
1 Huntington 5 Huntington * ** Key Words : Huntington disease, polyglutamine disease Huntington Huntington s disease HD HD Huntington HD Huntington HD 1872 George Huntington 1 HD HD Huntingtin HTTCAG HD I Huntington , /10 Fig HD HD HD 5 II Huntingtin HTT HTT I CAG interme diate allele HD 40 HDCAG Q HD polyq disease HTT Qn Qn HD Qn homozygotes heterozygotes Qn anticipation Qn Qn Huntington s Disease Epidemiology, Diagnosis, Treatment. Kazuko HASEGAWA : National Hospital Organization, Sagamihara National Hospital Vol. 32 No
2 Huntington HD Fig. 1 Prevalence of Huntington s disease in Japan huntingtin Huntingtin Huntingtin post translational modification huntingtin III Table 1 3, 4 1. HD HDTable 1 Fig HD motor impersistance initial saccade ocular motor apraxia grimacing 3. 4 HD Vol. 32 No
3 Huntington Table 1 Motor & psychic symptoms in Huntington s disease HD Shannon Fig. 2 Clinical progression of Huntington s disease HD Vol. 32 No
4 Huntington HD 3 7 HD HD HD HD HD 4, 5 6, 7 4. Huntington HD HD westphal variant HD Choreopathy /3 2 3 IV MMSE FAB Vol. 32 No
5 Huntington V 1. tetrabenazine 8 tetrabenazine 9, 10 tetrabenazine sulpiride tiapride tetrabenazine reserpine benzodiazepine tetrabenazine clonazepam tetrabenazine amantadine 11, selective serotonin re uptake inhibitors SSRI benzodiazepine carbamazepine lamotrigine topiramate 14 SSRI SSRI clomipramine serotonin norepinephrine re uptake inhibi tors SNRIbenzodiazepine HD HD VI 15 VII Wilson neuronal ceroid lipo fucinosis DRPLA SCA17 SLE Schonlein Henoch HD ips HD HD 16 COI Vol. 32 No
6 Huntington 1 Michael R Hayden : Huntington s Chorea. Springer Verlag, Berlin, Heidelberg, New York, Huntington s Disease Collaborative Research Group : A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntingotn s disease chromosomes. The Hunting ton s Disease Collaborative Research Group. Cell 72 : , Shannon KM : Huntington s disease clinical signs, symptoms, presymptomatic diagnosis, and diagnosis. Handbook of Clini cal Neurology Weinerm WJ, Tolosa E ed, Vol 100 Chap 1, Elsevier science publishers, Anderson KE : Huntington s disease. Handbook of Clinical Neurology Weinerm WJ, Tolosa E ed, Vol 100 Chap 2, Elsevi er science publishers, Mohr E, Brouwers P, Claus JJ et al : Visuospatial cognition in Huntington s disease. Mov Disord 6 : , Stout JC, Rodawalt WC, Siemers ER : Risky decision making in Huntington s disease. J Int Neuropsychol Soc 7 : , Ribai P, Nguyen K, Hahn Barma V et al : Psychiatric and cog nitive difficulties as indicators of Juvenile Huntington disease onset in 29 patients. Arch Neurol 64 : , Jankovic J : Treatment of hyperkinetic movement disorders. Lancet Neurol 18 : , Huntington study group : A randomized, double blind, place bo controlled trial of tetrabenazine as antichorea therapy in Huntington s disease. Neurology 66 : , Burgunder JM, Guttman M, Periman S et al : An international survey based algorithm for the pharmacologic treatment of chorea in Huntington s disease. PLos Curr 2011 Aug 30;3 RRN1260. Doi: /currents.RRN O Suilleabhain P, Dewey RB : A randomized trial of amanta dine in Huntington s disease. Arch Neurol 60 : , Lucetti C, Del Dotto P, Gambaccini G et al : IV amantadine im proved chorea in Huntington s disease. An acute randomized, controlled study. Neurology 60 : , Groves M, van Duijin E, Anderson K : An international survey based algorithm for the pharmacologic treatment of irritabili ty in Huntington s disease. PLoS Curr 2011 Aug 30:RRN1259. doi; /currents.rrn Anderson K, Craufurd D, Edmondson MC et al : An interna tional survey based algorithm for the pharmacologic treat ment of obsessive compulsive behaviors in Huntington s dis ease. PLos Curr.2011 Sept 20;3 RRN1261. Doi: currents.rrn www.nanbyou.or.jp/ Vol. 32 No
Reach2HD Phase 2 Clinical Trial Top Line Results. Investor Conference Call 19 th February 2014
Reach2HD Phase 2 Clinical Trial Top Line Results Investor Conference Call 19 th February 2014 Safe Harbour This presentation may contain some statements that may be considered Forward-Looking Statements,
More informationHow to Effectively Manage the Motor Symptoms of HD
How to Effectively Manage the Motor Symptoms of HD Yvette Bordelon, MD, PhD Associate Clinical Professor of Neurology David Geffen School of Medicine at UCLA The information provided by speakers in workshops,
More informationORIGINAL CONTRIBUTION
Dystonia-Predominant Adult-Onset Huntington Disease Association Between Motor Phenotype and Age of Onset in Adults ORIGINAL CONTRIBUTION Elan D. Louis, MD, MS; Karen E. Anderson, MD; Carol Moskowitz, RN;
More informationNeuroscience 410 Huntington Disease - Clinical. March 18, 2008
Neuroscience 410 March 20, 2007 W. R. Wayne Martin, MD, FRCPC Division of Neurology University of Alberta inherited neurodegenerative disorder autosomal dominant 100% penetrance age of onset: 35-45 yr
More informationPsychiatric symptoms are a common and debilitating
Med/Psych Update HUNTINGTON S DISEASE How to target psychiatric symptoms of Huntington s disease Clinical experience, limited evidence guide selection of symptom-focused treatments Lorin M. Scher, MD Health
More informationHuntington s Disease COGS 172
Huntington s Disease COGS 172 Overview Part I: What is HD? - Clinical description and features - Genetic basis and neuropathology - Cell biology, mouse models and therapeutics Part II: HD as a model in
More informationHuntington s disease
Parkinson's Disease Center and Movement Disorders Clinic 7200 Cambridge Street, 9th Floor, Suite 9A Houston, Texas 77030 713-798-2273 phone www.jankovic.org Huntington s disease Diagnosis Huntington s
More informationCurrent Pharmacological Approaches to Reduce Chorea in Huntington s Disease
Drugs (2017) 77:29 46 DOI 10.1007/s40265-016-0670-4 REVIEW ARTICLE Current Pharmacological Approaches to Reduce Chorea in Huntington s Disease Emma M. Coppen 1 Raymund A. C. Roos 1 Published online: 17
More information8/7/2017. Updates in Huntington s Disease AL Academy of Neurology Updates in HD Worldwide Prevalence of HD
Updates in Huntington s Disease AL Academy of Neurology 2017 Victor Sung, MD Director, UAB / HDSA Huntington s Disease Center of Excellence Updates in HD 2017 The UAB / HDSA Huntington s Disease Center
More informationVicki Wheelock MD. HDSA Center of Excellence at UC Davis June 5, 2009
Vicki Wheelock MD HDSA Center of Excellence at UC Davis June 5, 2009 The information provided by speakers in workshops, forums, sharing/networking sessions and any other educational presentation made as
More informationSymptomatic Treatment of Huntington Disease
Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics Symptomatic Treatment of Huntington Disease Octavian R. Adam and Joseph Jankovic Parkinson s Disease Center and
More informationHDSA welcomes you to Caregiver s Corner. Funded by an educational grant from
HDSA welcomes you to Caregiver s Corner Funded by an educational grant from Caregiver s Corner Webinar, DATE Managing Psychiatric Symptoms Peg Nopoulos, M.D. Professor of Psychiatry, Neurology, and Pediatrics
More informationXenazine. Xenazine (tetrabenazine) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Xenazine Page: 1 of 5 Last Review Date: June 12, 2014 Xenazine Description Xenazine (tetrabenazine)
More informationJuvenile Huntington s Disease
Juvenile Huntington s Disease A. Sasha Duffy, D.O. HDSA Center of Excellence at UC Davis Juvenile Huntington s Disease Genetically inherited neuropsychiatric degenerative disease Caused by abnormal CAG
More informationLongitudinal Psychiatric Symptoms in Prodromal Huntington s Disease: A Decade of Data
ARTICLES Longitudinal Psychiatric Symptoms in Prodromal Huntington s Disease: A Decade of Data Eric A. Epping, M.D., Ph.D., Ji-In Kim, Ph.D., David Craufurd, M.B.B.S., Thomas M. Brashers-Krug, M.D., Ph.D.,
More informationHunting for Huntington s
Focus on CME at The University of Western Ontario Hunting for Huntington s Varinder Dua, MBBS, FRCPC Presented at the CME for Regional Mental Health Care, February 2004 Huntington s disease (HD) is a well-defined,
More informationJuvenile-onset Huntington s disease
Juvenile-onset Huntington s disease Presenter Disclosures Martha A. Nance MD The following personal financial relationships with commercial interests relevant to this presentation existed during the past
More informationIntroduction to Huntington s Disease. Huntington s Disease Society of America Center of Excellence at UC Davis June 4, 2013
Introduction to Huntington s Disease Huntington s Disease Society of America Center of Excellence at UC Davis June 4, 2013 Welcome! HDSA Center of Excellence UC Davis Medical Center Vicki Wheelock MD,
More informationThe pathophysiology and pharmacological treatment of Huntington disease
Behavioural Neurology 26 (2013) 245 253 245 DOI 10.3233/BEN-2012-120267 IOS Press The pathophysiology and pharmacological treatment of Huntington disease Connie Pidgeon and Hugh Rickards The Michael Trimble
More informationProgression of motor subtypes in Huntington s disease: a 6-year follow-up study
J Neurol (2016) 263:2080 2085 DOI 10.1007/s00415-016-8233-x ORIGINAL COMMUNICATION Progression of motor subtypes in Huntington s disease: a 6-year follow-up study M. Jacobs 1 E. P. Hart 2 E. W. van Zwet
More informationSLEEP DISORDERS IN HUNTINGTON S DISEASE. Gary L. Dunbar, Ph.D.
SLEEP DISORDERS IN HUNTINGTON S DISEASE Gary L. Dunbar, Ph.D. Executive Director, Field Neurosciences Institute Co-Director, Program in Neuroscience Central Michigan University Pre-Talk Test 1. Which type
More informationVesicular Monoamine Transporter Type 2 Inhibitors: deutetrabenazine (Austedo ), tetrabenazine (Xenazine ), valbenazine (Ingrezza )
Vesicular Monoamine Transporter Type 2 Inhibitors: deutetrabenazine (Austedo ), tetrabenazine (Xenazine ), valbenazine (Ingrezza ) Applies to all products administered or underwritten by Blue Cross and
More informationORIGINAL CONTRIBUTION. Progression of Symptoms in the Early and Middle Stages of Huntington Disease
ORIGINAL CONTRIBUTION Progression of Symptoms in the Early and Middle Stages of Huntington Disease Sandra Close Kirkwood, PhD; Jessica L. Su, MS; P. Michael Conneally, PhD; Tatiana Foroud, PhD Objective:
More informationHuntington s Disease. An Update on Latest Research. HD Center of Excellence
Huntington s Disease An Update on Latest Research HD Treatment gcurrent treatments are symptomatic. gseveral compounds have delayed onset and slowed progression in mouse models. gquestion remains to translate
More informationHuntington s Disease Psychiatry. Christopher A. Ross MD PhD HDSA Convention June 6, Many slides adapted from Adam Rosenblatt, MD
Huntington s Disease Psychiatry Christopher A. Ross MD PhD HDSA Convention June 6, 2008 --Many slides adapted from Adam Rosenblatt, MD Huntington s Disease Society of America The information provided by
More informationDopamine Depleting Drugs
Parkinson's Disease Center and Movement Disorders Clinic 7200 Cambridge Street, 9th Floor, Suite 9A Houston, Texas 77030 713-798-2273 phone www.jankovic.org Dopamine Depleting Drugs Introduction Movement
More informationImproving clinical management and quality of life in mid to late stage Huntington s disease How research can inform clinical practice and vice versa
Improving clinical management and quality of life in mid to late stage Huntington s disease How research can inform clinical practice and vice versa Caroline Fisher, Anahita Brown, Katherine Sewell, Bronwyn
More informationLongitudinal Change in Gait and Motor Function in Pre-manifest Huntington s Disease
Longitudinal Change in Gait and Motor Function in Pre-manifest Huntington s Disease The purpose of this study was to examine longitudinal change in gait and motor function in pre-manifest Huntington s
More informationUniversity of Groningen. Biomarkers in premanifest Huntington's disease van Oostrom, Joost Cornelis Hendricus
University of Groningen Biomarkers in premanifest Huntington's disease van Oostrom, Joost Cornelis Hendricus IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 1Q18 January February
BRAND NAME Austedo TM GENERIC NAME Deutetrabenazine MANUFACTURER Teva Pharmaceuticals USA, Inc. DATE OF APPROVAL August 30, 2017 PRODUCT LAUNCH DATE Currently commercially available REVIEW TYPE Review
More informationDrugs used in Huntington s. disease
Drugs used in Huntington s HD can intensify in next generation disease The number of CAG repeats The age in which the symptom of HD to appear healthy person ill person dead person Drugs used in Huntington
More informationLecture 1 Huntington s Disease
Lecture 1 Huntington s Disease David Saffen, Ph.D. Principal Investigator Department of Cellular and Genetic Medicine Fudan University, Shanghai, China Email: saffen@fudan.edu.cn Huntington s disease (HD)
More informationPsych 3102 Lecture 3. Mendelian Genetics
Psych 3102 Lecture 3 Mendelian Genetics Gregor Mendel 1822 1884, paper read 1865-66 Augustinian monk genotype alleles present at a locus can we identify this? phenotype expressed trait/characteristic can
More informationSubject: Austedo (deutetrabenazine) Original Effective Date: 3/8/2018. Policy Number: MCP-307. Revision Date(s):
Subject: Austedo (deutetrabenazine) Original Effective Date: 3/8/2018 Policy Number: MCP-307 Revision Date(s): Review Date: 3/8/2018 MCPC Approval Date: 3/8/2018 DISCLAIMER This Molina Clinical Policy
More informationAustedo. Austedo (deutetrabenazine) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.15 Subject: Austedo Page: 1 of 6 Last Review Date: September 15, 2017 Austedo Description Austedo
More informationTetrabenazine (Xenazine), An FDA-Approved Treatment Option For Huntington s Disease Related Chorea
Tetrabenazine (Xenazine), An FDA-Approved Treatment Option For Huntington s Disease Related Chorea Tatiana Yero, PharmD, BS, and Jose A. Rey, PharmD, BCPP Key words: tetrabenazine, Xenazine, Huntington
More informationMedications and Non-Pharma Approaches to Treatment. David J. Irwin, MD Penn Frontotemporal Degeneration Center
Medications and Non-Pharma Approaches to Treatment David J. Irwin, MD Penn Frontotemporal Degeneration Center Outline Non-Pharmacological Treatment Strategies Behavior Language Motor Supportive Care Check-points
More informationPsychiatric Issues in Patients with Huntington's Disease. Disclosures. Huntington s Disease. Disease Course. Huntington s Disease
Psychiatric Issues in Patients with Huntington's Disease SCPA Sunday, January 27, 2019 Robert Breen, M.D. South Carolina Department of Mental Health University of South Carolina School of Medicine 1 2
More informationJuvenile Huntington Disease
Juenile Huntington Disease THE RAREST HD VARIANT when the disease starts before 20 years of age Ferdinando Squitieri M.D., Ph.D. - Neurologist, Head of the HD Unit, IRCCS Casa Sollieo della Sofferenza
More informationNeuropathology of Neurodegenerative Disorders Prof. Jillian Kril
Neurodegenerative disorders to be discussed Alzheimer s disease Lewy body diseases Frontotemporal dementia and other tauopathies Huntington s disease Motor Neuron Disease 2 Neuropathology of neurodegeneration
More informationUnderstanding Huntington s disease (HD)
Understanding Huntington s disease (HD) This series of infographics are designed as a tool to aid discussions with your patients and as a teaching guide These materials focus on enhancing the understanding
More informationHuntington s disease
Clinical Review For the full versions of these articles see bmj.com Huntington s disease Marianne J U Novak, 1 2 Sarah J Tabrizi 1 3 1 National Hospital for Neurology and Neurosurgery, London WC1N 3BG
More informationWHODAS 2.0 in prodromal Huntington disease: measures of functioning in neuropsychiatric disease
(2014) 22, 958 963 & 2014 Macmillan Publishers Limited All rights reserved 1018-4813/14 www.nature.com/ejhg ARTICLE WHODAS 2.0 in prodromal Huntington disease: measures of functioning in neuropsychiatric
More informationIntroduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More informationMedications for Early/Mid Stage HD
Medications for Early/Mid Stage HD Robert Y. Moore, MD, PhD, FAAN Love Family Professor Department of Neurology University of Pittsburgh Director, Huntington s s Disease Program University of Pittsburgh-UPMC
More informationThe Current Clinical Management of Huntington s Disease
Movement Disorders Vol. 23, No. 11, 2008, pp. 1491 1504 Ó 2008 Movement Disorder Society CME Reviews The Current Clinical Management of Huntington s Disease Wendy Phillips, MD, 1,2 Kathleen M. Shannon,
More informationDifficulty modifying a sustained motor response in prodromal Huntington s disease
JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY 2012, ifirst,1 6 Difficulty modifying a sustained motor response in prodromal Huntington s disease Laura Mickes 1,JohnT.Wixted 1,GuerryM.Peavy 2,MarkW.Jacobson
More informationClinical Medicine: Therapeutics. Tetrabenazine in Huntington s Disease Chorea. Shilpa Chitnis and Cherian Abraham Karunapuzha
Clinical Medicine: Therapeutics R e v i e w Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Tetrabenazine in Huntington s Disease Chorea Shilpa Chitnis and
More informationClass Review with New Drug Evaluations: Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationFirst described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy"
Parkinson's Disease First described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy" Parkinson s disease (PD) is a neurological disorder characterized by a progressive
More informationTHE MANAGEMENT OF NEURODEGENERATIVE THE MANAGEMENT OF NEURODEGENERATIVE SYMPTOMS IN HUNTINGTON S DISEASE SYMPTOMS IN HUNTINGTON S DISEASE
Volume 24, Issue 5 February 2009 THE MANAGEMENT OF NEURODEGENERATIVE SYMPTOMS IN HUNTINGTON S DISEASE Chad Madill, Pharm.D. Candidate Huntington s disease (HD) is a genetically programmed disease in which
More informationClass Review with New Drug Evaluations: Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationORIGINAL CONTRIBUTION. Specific Psychiatric Manifestations Among Preclinical Huntington Disease Mutation Carriers
ORIGINAL CONTRIBUTION Specific Psychiatric Manifestations Among Preclinical Huntington Disease Mutation Carriers Jeanine Marshall, BS; Kerry White, MS; Marjorie Weaver, MS; Leah Flury Wetherill, MS; Siu
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/37384 holds various files of this Leiden University dissertation. Author: Hubers, Anna Alida Maria (Marloes) Title: Suicidality in Huntington's disease
More informationXenazine. Xenazine (tetrabenazine) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.12 Subject: Xenazine Page: 1 of 5 Last Review Date: December 8, 2017 Xenazine Description Xenazine
More informationHDSA Annual Convention June 2013 Behavior Issues: Irritability and Depression Peg Nopoulos, M.D.
HDSA Annual Convention June 2013 Behavior Issues: Irritability and Depression Peg Nopoulos, M.D. Professor of Psychiatry, Neurology, and Pediatrics University of Iowa, Iowa City, Iowa The information provided
More informationJuvenile Huntington s Disease. Josh Dayananthan, MD Movement Disorders Fellow HDSA Center of Excellence at UC Davis Medical Center
Juvenile Huntington s Disease Josh Dayananthan, MD Movement Disorders Fellow HDSA Center of Excellence at UC Davis Medical Center What is JHD? Huntington s disease (HD) is an inherited neuropsychiatric
More informationFrequently Asked Questions About Upcoming Genentech/Roche Studies
Frequently Asked Questions About Upcoming Genentech/Roche Studies On Wednesday, September 26 th, HDSA hosted a webinar presented by Genentech/Roche in which representatives from their Huntington s disease
More informationPart 1 Parkinson s Disease. COGS 172: Brain Disorders and Cogni5on
Part 1 Parkinson s Disease COGS 172: Brain Disorders and Cogni5on Background: Neuroanatomy of the motor system Note: Given short time to the final the details of the anatomy will not be in the exam, but
More informationTreatment of Irritability in Huntington s Disease
Current Treatment Options in Neurology (2010) 12:424 433 DOI 10.1007/s11940-010-0088-3 Psychiatric Manifestations of Neurologic Disease Treatment of Irritability in Huntington s Disease Erik van Duijn,
More informationSubject: Xenazine (tetrabenazine) Original Effective Date: 12/3/09. Policy Number: MCP-075 Revision Date(s): 10/30/2013; 7/10/2018
Subject: Xenazine (tetrabenazine) Original Effective Date: 12/3/09 Policy Number: MCP-075 Revision Date(s): 10/30/2013; 7/10/2018 Review Date(s): 12/16/15; 6/15/2016; 3/21/2017 MCPC Approval Date: DISCLAIMER
More informationIt s time. for a new approach to treat chronic neurological diseases Adamas Pharmaceuticals, Inc. All Rights Reserved.
It s time for a new approach to treat chronic neurological diseases Forward-looking statements Statements contained in this presentation regarding expected future events are forward-looking statements
More informationHuntington Disease and Other Choreas
Huntington Disease and Other Choreas Francisco Cardoso, MD, PhD KEYWORDS Chorea Ballism Huntington disease Neuroacanthocytosis Sydenham chorea Vascular chorea Chorea is a syndrome characterized by brief,
More informationin HD Research Stem Cells and DNA Repair 2018 HDSA Annual Convention June 7-9, 2018 Los Angeles, CA
in HD Research Stem Cells and DNA Repair 2018 HDSA Annual Convention June 7-9, 2018 Los Angeles, CA HD: A Family Disease HD: A Family Disease ca 1920 1938 1980 2007 Joining the HD Research Community What
More informationProfessor Tim Anderson
Professor Tim Anderson Neurologist University of Otago Christchurch 11:00-11:55 WS #91: Shakes Jerks and Spasms - Recognition and Differential Diagnosis 12:05-13:00 WS #102: Shakes Jerks and Spasms - Recognition
More informationThank you for your ongoing support and interest in the investigational medicine RG6042 for Huntington s disease (HD).
16 September 2018 Update on RG6042 (formerly known as IONIS-HTT Rx ) Huntington s disease global development programme: Two clinical studies to begin by end of 2018 Dear Global Huntington s Community,
More informationXenazine. Xenazine (tetrabenazine) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Xenazine Page: 1 of 5 Last Review Date: November 30, 2018 Xenazine Description Xenazine (tetrabenazine)
More informationCHOREA AND DYSTONIA. Joohi Jimenez-Shahed, MD Baylor College of Medicine Houston, TX
CHOREA AND DYSTONIA Joohi Jimenez-Shahed, MD Baylor College of Medicine Houston, TX INTRODUCTION The key to successful differential diagnosis and treatment of patients with movement disorders is successful
More informationParkinson s Disease. Sirilak yimcharoen
Parkinson s Disease Sirilak yimcharoen EPIDEMIOLOGY ~1% of people over 55 years Age range 35 85 years peak age of onset is in the early 60s ~5% of cases characterized by an earlier age of onset (typically
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/32744 holds various files of this Leiden University dissertation Author: Heemskerk, Anne-Wil Title: Dysphagia in Huntington s disease Issue Date: 2015-04-15
More informationJay M. Baraban MD, PhD January 2007 GENES AND BEHAVIOR
Jay M. Baraban MD, PhD jay.baraban@gmail.com January 2007 GENES AND BEHAVIOR Overview One of the most fascinating topics in neuroscience is the role that inheritance plays in determining one s behavior.
More informationProfessor Tim Anderson
Professor Tim Anderson Neurologist University of Otago Christchurch 11:00-11:55 WS #91: Shakes Jerks and Spasms - Recognition and Differential Diagnosis 12:05-13:00 WS #102: Shakes Jerks and Spasms - Recognition
More informationIndex. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers
Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) a-adrenergic blockers for PTSD, 798 b-adrenergic blockers for PTSD, 798 Adrenergic
More informationPsychology of patients with amyotrophic lateral sclerosis (ALS) compared with that of cancer patients
Original Contribution Kitasato Med J 2014; 44: 6-11 Psychology of patients with amyotrophic lateral sclerosis (ALS) compared with that of cancer patients Masafuchi Ryoh, 1 Kazuko Hasegawa, 2 Eimei Furusawa,
More informationPharmacy Prior Authorization GMH/SA and Non-Title 19/21 SMI Non-Formulary and Prior Authorization Guidelines
Brand Name Medication Requests Non-Formulary Medications GMH/SA and Non- 19/21 SMI Mercy Care requires use of generic agents that are considered therapeutically equivalent by the FDA. For authorization
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/32744 holds various files of this Leiden University dissertation Author: Heemskerk, Anne-Wil Title: Dysphagia in Huntington s disease Issue Date: 2015-04-15
More informationDentatorubral-pallidoluysian atrophy (DRPLA)
Neuropathology 2010; 30, 453 457 doi:10.1111/j.1440-1789.2010.01120.x The 50th Anniversary of Japanese Society of Neuropathology Memorial Symposium: Milestones in Neuropathology from Japan Dentatorubral-pallidoluysian
More informationFactors Contributing to Institutionalization in Patients with Huntington s Disease
RESEARCH ARTICLE Factors Contributing to Institutionalization in Patients with Huntington s Disease Adam Rosenblatt, MD,* Brahma V. Kumar, Russell L. Margolis, MD, Claire S. Welsh, and Christopher A. Ross,
More informationSEIZURES AND DEPRESSION
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences SEIZURES AND DEPRESSION JENNIFER M. ERICKSON, DO PSYCHIATRY CONSULT AND TELEPSYCHIATRY DEPARTMENT OF PSYCHIATRY
More informationThe motor regulator. 1) Basal ganglia/nucleus
The motor regulator 1) Basal ganglia/nucleus Neural structures involved in the control of movement Basal Ganglia - Components of the basal ganglia - Function of the basal ganglia - Connection and circuits
More informationNeurological Disorders and Purinergic Metabolic Disruption. By: Nhi, Alex, Teva, and Guadalupe
Neurological Disorders and Purinergic Metabolic Disruption By: Nhi, Alex, Teva, and Guadalupe Lesch-Nyhan Disease Discovered by Michael Lesch and WIlliam Nyhan in 1964 Causes: Disruption of purine metabolism
More informationHuntington s Disease and HD-like Disorders Prof. Sarah Tabrizi MD PhD FMedSci
Huntington s Disease and HD-like Disorders UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery Queen Square London 1 Genetic causes of chorea: HD and HD-like disorders (HD phenocopies)
More informationCognitive and Psychiatric Characteristics of Huntington Disease. Rosa Ip, PhD, C. Psych, Jean Byers. MD., FRCPC, DABPN, Carol Harren, RN, CNC
Cognitive and Psychiatric Characteristics of Huntington Disease Rosa Ip, PhD, C. Psych, Jean Byers. MD., FRCPC, DABPN, Carol Harren, RN, CNC Cognitive and Psychiatric Characteristics of Huntington Disease
More informationA clinical classification acknowledging neuropsychiatric and cognitive impairment in Huntington s disease
Vinther-Jensen et al. Orphanet Journal of Rare Diseases 2014, 9:114 RESEARCH Open Access A clinical classification acknowledging neuropsychiatric and cognitive impairment in Huntington s disease Tua Vinther-Jensen
More informationUnified Huntington s Disease Rating Scale: clinical practice and a critical approach
Unified Huntington s Disease Rating Scale: clinical practice and a critical approach Jiří Klempíř a Olga Klempířová a Nataša Špačková a Jana Židovská b Jan Roth a a Department of Neurology, Charles University,
More informationLIHR La ricerca sulle malattie rare e le prospettive di cura per la malattia di Huntington. Neuroscience, the Future is Bright
LIHR La ricerca sulle malattie rare e le prospettive di cura per la malattia di Huntington Neuroscience, the Future is Bright Mauro Patroncini, MD Pipeline Product Strategy Leader Luisa De Stefano Head
More informationWords: 1393 (excluding table and references) Exploring the structural relationship between interviewer and self-rated affective
Interviewer and self-rated affective symptoms in HD 1 Words: 1393 (excluding table and references) Tables: 1 Corresponding author: Email: Maria.Dale@leicspart.nhs.uk Tel: +44 (0) 116 295 3098 Exploring
More informationAnxiety in Huntington s Disease
SPECIAL ARTICLES Anxiety in Huntington s Disease Maria Dale, D.Clin.Psy., and Erik van Duijn, M.D., Ph.D. Anxiety is common in Huntington s disease (HD), though it has been under-researched. The authors
More informationHuman Genetic Diseases. AP Biology
Human Genetic Diseases 1 2 2006-2007 3 4 5 6 Pedigree analysis Pedigree analysis reveals Mendelian patterns in human inheritance data mapped on a family tree = male = female = male w/ trait = female w/
More informationClinical Aspects of Movement Disorders:
Clinical Aspects of Movement Disorders: 2 Effects on Walking and Posture Henrique Ballalai Ferraz and Roberta Arb Saba Abstract Movement disorders are a group of syndromes which includes parkinsonism,
More informationAmerican Psychiatric Nurses Association
Francis J. McMahon International Society of Psychiatric Genetics Johns Hopkins University School of Medicine Dept. of Psychiatry Human Genetics Branch, National Institute of Mental Health* * views expressed
More informationPsychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD
Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, MD Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, M.D. Health Sciences
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/32744 holds various files of this Leiden University dissertation Author: Heemskerk, Anne-Wil Title: Dysphagia in Huntington s disease Issue Date: 2015-04-15
More informationA randomized controlled clinical trial of Citalopram versus Fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD)
Eur Child Adolesc Psychiatry (2009) 18:131 135 DOI 10.1007/s00787-007-0634-z ORIGINAL CONTRIBUTION Javad Alaghband-Rad Mitra Hakimshooshtary A randomized controlled clinical trial of Citalopram versus
More informationThe Safety and Efficacy of Ondansetron in the Treatment of Obsessive Compulsive Disorder
Duquesne University Duquesne Scholarship Collection Graduate Student Research Symposium The 4th Annual Graduate Student Research Symposium September 19, 2017 The Safety and Efficacy of Ondansetron in the
More informationHyperkinetic movement disorders are. Hyperkinetic Movement Disorders. Cases in Movement Disorders. James case. About Tom
Hyperkinetic Movement Disorders Sarah Furtado, MD, PhD, FRCPC James case A mother brings her son James, 10, to your office because of repetitive sniffing sounds and repetitive eye blinking. This sniffing
More informationEpilepsy and Epileptic Seizures
Epilepsy and Epileptic Seizures Petr Marusič Dpt. of Neurology Charles University, Second Faculty of Medicine Motol University Hospital Diagnosis Steps Differentiation of nonepileptic events Seizure classification
More informationTranscranial sonography in movement disorders
Transcranial sonography in movement disorders Uwe Walter 1st Residential Training of the European Society of Neurosonology and Cerebral Hemodynamics September 7-12, 2008 Bertinoro, Italy Department of
More information